TOVX Theriva Biologics Inc

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: TOVX

Price (delayed)

$0.3686

Market cap

$6.32M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.14

Enterprise value

-$14.8M

Synthetic Biologics, Inc. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company's ...

Highlights
Theriva Biologics's EPS has increased by 13% YoY and by 10% from the previous quarter
The net income has increased by 7% YoY and by 5% QoQ
The debt has increased by 28% year-on-year but it has declined by 3.1% since the previous quarter
The quick ratio has decreased by 42% YoY and by 3.6% from the previous quarter
TOVX's equity is down by 29% YoY and by 10% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.syntheticbiologics.com
Peers: OMER OMGA

Key stats

What are the main financial stats of TOVX
Market
Shares outstanding
17.15M
Market cap
$6.32M
Enterprise value
-$14.8M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.17
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$19.99M
EBITDA
-$19.47M
Free cash flow
-$19.2M
Per share
EPS
-$1.14
Free cash flow per share
-$1.19
Book value per share
$2.17
Revenue per share
$0
TBVPS
$3.07
Balance sheet
Total assets
$55.22M
Total liabilities
$15.52M
Debt
$2.15M
Equity
$36.96M
Working capital
$20.67M
Liquidity
Debt to equity
0.06
Current ratio
4.07
Quick ratio
3.45
Net debt/EBITDA
1.09
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-29.3%
Return on equity
-42.9%
Return on invested capital
-101.7%
Return on capital employed
-41.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TOVX stock price

How has the Theriva Biologics stock price performed over time
Intraday
-3%
1 week
-14.28%
1 month
-29.12%
1 year
-45.79%
YTD
-14.3%
QTD
-21.41%

Financial performance

How have Theriva Biologics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$21.43M
Net income
-$18.35M
Gross margin
N/A
Net margin
N/A
The net income has increased by 7% YoY and by 5% QoQ
The company's operating income rose by 4.9% QoQ

Growth

What is Theriva Biologics's growth rate over time

Valuation

What is Theriva Biologics stock price valuation
P/E
N/A
P/B
0.17
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Theriva Biologics's EPS has increased by 13% YoY and by 10% from the previous quarter
TOVX's equity is down by 29% YoY and by 10% from the previous quarter
TOVX's P/B is 15% below its last 4 quarters average of 0.2

Efficiency

How efficient is Theriva Biologics business performance
The ROE is down by 27% YoY and by 3.1% QoQ
The return on invested capital is up by 26% year-on-year and by 8% since the previous quarter
The ROA has contracted by 18% YoY

Dividends

What is TOVX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TOVX.

Financial health

How did Theriva Biologics financials performed over time
The quick ratio has decreased by 42% YoY and by 3.6% from the previous quarter
Theriva Biologics's current ratio has decreased by 37% YoY but it has increased by 2.3% from the previous quarter
The debt is 94% smaller than the equity
The debt to equity has soared by 100% YoY and by 20% from the previous quarter
TOVX's equity is down by 29% YoY and by 10% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.